These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 32440095)

  • 21. Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
    Smith BD; Kaufman MD; Wise SC; Ahn YM; Caldwell TM; Leary CB; Lu WP; Tan G; Vogeti L; Vogeti S; Wilky BA; Davis LE; Sharma M; Ruiz-Soto R; Flynn DL
    Mol Cancer Ther; 2021 Nov; 20(11):2098-2109. PubMed ID: 34433663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
    Peterfy C; Chen Y; Countryman P; Chmielowski B; Anthony SP; Healey JH; Wainberg ZA; Cohn AL; Shapiro GI; Keedy VL; Singh A; Puzanov I; Wagner AJ; Qian M; Sterba M; Hsu HH; Tong-Starksen S; Tap WD
    Future Oncol; 2022 Apr; 18(12):1449-1459. PubMed ID: 35040698
    [No Abstract]   [Full Text] [Related]  

  • 23. Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.
    Yin O; Wagner AJ; Kang J; Knebel W; Zahir H; van de Sande M; Tap WD; Gelderblom H; Healey JH; Shuster D; Stacchiotti S
    J Clin Pharmacol; 2021 Apr; 61(4):480-492. PubMed ID: 33043474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations.
    Vaynrub A; Healey JH; Tap W; Vaynrub M
    Onco Targets Ther; 2022; 15():53-66. PubMed ID: 35046667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
    van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
    J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
    Ravi V; Wang WL; Lewis VO
    Curr Opin Oncol; 2011 Jul; 23(4):361-6. PubMed ID: 21577109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
    Lee JH; Chen TW; Hsu CH; Yen YH; Yang JC; Cheng AL; Sasaki SI; Chiu LL; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin CC
    Invest New Drugs; 2020 Feb; 38(1):99-110. PubMed ID: 30825104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RNAscope CSF1 chromogenic in situ hybridization: a potentially useful tool in the differential diagnosis of tenosynovial giant cell tumors.
    Thangaiah JJ; Koepplin JW; Folpe AL
    Hum Pathol; 2021 Sep; 115():1-9. PubMed ID: 34058245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
    Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
    Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pexidartinib Upfront in a Case of Tenosynovial Giant Cell Tumor: Proof of Concept for a Treatment Paradigm Shift.
    Palmerini E; Peta G; Tuzzato G
    Oncol Ther; 2024 Dec; 12(4):833-841. PubMed ID: 39155359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
    Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extensile Anterior and Posterior Knee Exposure for Complete Synovectomy of Diffuse Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis).
    Lingamfelter M; Novaczyk ZB; Cheng EY
    JBJS Essent Surg Tech; 2022; 12(2):. PubMed ID: 36741035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
    Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
    Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor.
    Tap WD; Healey JH
    Tumour Biol; 2022; 44(1):239-248. PubMed ID: 36502356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.
    Healey JH; Tap WD; Gelhorn HL; Ye X; Speck RM; Palmerini E; Stacchiotti S; Desai J; Wagner AJ; Alcindor T; Ganjoo K; Martín-Broto J; Wang Q; Shuster D; Gelderblom H; van de Sande M
    Clin Orthop Relat Res; 2023 Jan; 481(1):107-116. PubMed ID: 36001000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
    Gelderblom H; Razak AA; Taylor MH; Bauer TM; Wilky B; Martin-Broto J; Gonzalez AF; Rutkowski P; Szostakowski B; Alcindor T; Saleh R; Genta S; Stacchiotti S; van de Sande M; Wagner AJ; Bernthal N; Davis LE; Vuky J; Tait C; Matin B; Narasimhan S; Sharma MG; Ruiz-Soto R; Sherman ML; Tap WD
    Clin Cancer Res; 2024 Sep; 30(18):3996-4004. PubMed ID: 38995311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients.
    Niu X; Ravi V; Shan B; Guo Q; Shi H; Zou Q; Gelderblom H
    Future Oncol; 2024 Sep; ():1-8. PubMed ID: 39287124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.
    Robert M; Farese H; Miossec P
    Front Immunol; 2022; 13():820046. PubMed ID: 35265077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol.
    Takeuchi A; Nomura A; Yamamoto N; Hayashi K; Igarashi K; Tandai S; Kawai A; Matsumine A; Miwa S; Nishida Y; Nakamura T; Terauchi R; Hoshi M; Kunisada T; Endo M; Yoshimura K; Murayama T; Tsuchiya H
    BMC Musculoskelet Disord; 2019 Feb; 20(1):68. PubMed ID: 30738433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.
    Staals EL; Ferrari S; Donati DM; Palmerini E
    Eur J Cancer; 2016 Aug; 63():34-40. PubMed ID: 27267143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.